Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/SCYNEXIS, Inc./ 4

SEC Filing · 4

SCYNEXIS, Inc.

SCYXNASDAQEQUITYCurrent

SEC Filing

Filed Sep 22, 2026Accepted Sep 22, 2026, 4:02 PM EDTCIK 1178253Accession 0001193125-26-397873
View company →Permanent SEC source ↗
Share

Company context

SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.

Current securities

SCYXNASDAQ · EQUITY · Current

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 22, 2026
  2. 4 filingSep 11, 2026
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsSep 10, 2026
  4. SCHEDULE 13G/A filingAug 14, 2026
  5. SCHEDULE 13G/A filingAug 14, 2026

As-filed source

Primary evidence
As filedOpen full document ↗